Labetalol
Mostrando 1-12 de 12 artigos, teses e dissertações.
-
1. Está indicado o uso de AAS na gestante hipertensa?
O uso de antiagregantes plaquetários em pequenas doses diárias (75 a 100mg) tem sido recomendado para gestantes com risco aumentado para desenvolver pré-eclâmpsia (1). Os principais fatores de risco para o desenvolvimento da pré-eclâmpsia são primigestação, história prévia ou familiar, hipertensão crônica, diabetes, colagenose, raça neg
Núcleo de Telessaúde Sergipe. Publicado em: 12/06/2023
-
2. Tratamento da pré-eclâmpsia baseado em evidências
As síndromes hipertensivas na gestação merecem especial destaque no cenário da saúde pública mundial. Atualmente, respondem como terceira causa de mortalidade materna no mundo e primeira no Brasil. Do ponto de vista prático, a pré-eclâmpsia continua sendo uma síndrome que leva a graves repercussões maternas e fetais, conhecendo-se ainda pouco sobr
Revista Brasileira de Ginecologia e Obstetrícia. Publicado em: 2010-09
-
3. Influência do diabetes mellitus gestacional na disposição cinética e metabolismo estereosseletivos do labetalol em pacientes com hipertensão arterial / Influence of gestational diabetes mellitus on the kinetic disposition and stereoselective metabolism of labetalol in patients with arterial hypertension,
Labetalol, a hypertensive agent considered to be safe for use by pregnant women, is clinically available as a mixture of two racemates, with the (R,R) isomer being a antagonist and the (S,R) isomer being responsible for the blocking activity. The study investigated the influence of gestational diabetes mellitus (GDM) on the kinetic disposition and stereosele
Publicado em: 2009
-
4. Pharmacological basis for antihypertensive effects of intravenous labetalol.
Labetalol 1-5 mg/kg administered intravenously to normal subjects in the supine position produced an immediate mean fall in systolic (16%) and diastolic (25%) blood pressure with a concomitant increase in heart rate (12%). After graded exercise, intravenous labetalol inhibited increases in heart rate and blood pressure. Isoprenaline log dose response curves
-
5. Effects of combined alpha and beta adrenoceptor blockade in patients with angina pectoris. A double blind study comparing labetalol with placebo.
The effects of a combined alpha and beta receptor antagonist, labetalol, were investigated in 10 patients with chronic stable angina pectoris. The optimal dose was determined during an initial dose titration study when the patients were treated with 200 mg, 400 mg, and 600 mg (six patients) of labetalol a day. The effective dose was then compared with placeb
-
6. Metabolic and haemodynamic effects of increased circulating adrenaline in man. Effect of labetalol, an alpha and beta blocker.
To simulate increased sympathoadrenal activity adrenaline was infused in normotensive subjects to achieve plasma adrenaline concentrations similar to those seen after myocardial infarction or hypoglycaemia. Adrenaline was infused after pretreatment for five days with labetalol 200 mg twice daily or placebo given in a random order. The rise in systolic blood
-
7. Treatment of hypertension in acute stage of myocardial infarction. Haemodynamic effects of labetalol.
Labetalol was used to treat systemic hypertension (systolic blood pressure above 150 mmHg) in 11 patients with acute myocardial infarction; its haemodynamic effects and tolerance were studied. Increasing doses of labetalol were infused to lower systolic blood pressure to less than 130 mmHg; the optimal rate was then maintained for one hour (mean rate: 2.3 mg
-
8. Comparative haemodynamic dose response effects of propranolol and labetalol in coronary heart disease.
The immediate haemodynamic dose response effects of beta blockade (propranolol: 2 to 16 mg) were compared with those of combined alpha beta blockade (labetalol: 10 to 80 mg) in a randomised study of 20 patients with stable angina pectoris. After control measurements, the circulatory changes induced by four logarithmically cumulative intravenous boluses of ea
-
9. Oral labetalol in the management of stable angina pectoris in normotensive patients.
The efficacy of labetalol, an alpha and beta receptor antagonist, was evaluated in 12 normotensive patients with stable angina pectoris in a single blind dose ranging study. After a two week period of placebo treatment, labetalol was given in doses of 100, 150, 200, and 300 mg twice daily, each for two weeks. Frequency of angina attacks decreased from 9.4 (S
-
10. Haemodynamic adaptation at rest and during exercise to long-term antihypertensive treatment with combined alpha- and beta-adrenoreceptor blockade by labetalol.
-
11. Role of vascular alpha-2 adrenoceptors in regulating lipid mobilization from human adipose tissue.
The role of alpha-2 adrenoceptors in lipid mobilization and blood flow was investigated in situ using microdialysis of subcutaneous adipose tissue in nonobese healthy subjects. The alpha-2 agonist clonidine caused dose-dependent biphasic response with increased glycerol levels at low clonidine concentrations and decreased glycerol levels at concentrations >
-
12. Controlled release from triple layer, donut-shaped tablets with enteric polymers
The purpose of this research was to evaluate triple layer, donut-shaped tablets (TLDSTs) for extended release dosage forms. TLDSTs were prepared by layering 3 powders sequentially after pressing them with a punch. The core tablet consisted of enteric polymers, mainly hydroxypropyl methylcellulose acetate succinate, and the bottom and top layers were made of
Springer-Verlag.